search
Back to results

Changing Tactics? Optimizing ECT in Difficult-to-treat Depression (ChaT)

Primary Purpose

Depression

Status
Recruiting
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
switch to BT electrode position
continue with RUL electrode position
Sponsored by
Universitaire Ziekenhuizen KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression focused on measuring Electroconvulsive Therapy, Depression, Cognition

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures Age 18 or older Diagnosis of major depressive disorder (DSM-5 296.21-30) or bipolar disorder, depressed (DSM-5 296.51-54; 296.84), confirmed by MINI (Mini International Neuropsychiatric Interview) Exclusion Criteria: Contra-indication for general anesthesia Non-Dutch speaking Diagnosis of schizoaffective disorder or schizophrenia, confirmed by MINI Diagnosis of substance use disorder in the past six months, confirmed by MINI Diagnosis of neurocognitive disorder or intellectual disability alongside a MoCA score <23 Previous ECT course in the past three months Participation in an interventional Trial with an investigational medicinal product or device Pregnancy

Sites / Locations

  • UPC KortenbergRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

BT ECT

RUL ECT

Arm Description

Participants showing no response will be switched to BT ECT until remission is achieved.

Participants showing no response will continue with RUL ECT until remission is achieved.

Outcomes

Primary Outcome Measures

Change form baseline Depressive Symptom Severity
mean scores on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR)
Change form baseline Depressive Symptom Severity
mean scores on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR)
Depressive Symptom Severity
mean scores on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR)
Depressive Symptom Severity
mean scores on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR)
Autobiographical Memory
Mean scores on the Colombia University Autobiographical Memory Interview Short Form (CU-AMI-SF)
Autobiographical Memory
Mean scores on the Colombia University Autobiographical Memory Interview Short Form (CU-AMI-SF)
Autobiographical Memory
Mean scores on the Colombia University Autobiographical Memory Interview Short Form (CU-AMI-SF)
Autobiographical Memory
Mean scores on the Colombia University Autobiographical Memory Interview Short Form (CU-AMI-SF)

Secondary Outcome Measures

Response/remission status
number of participants with an 50 percent decrease in IDS-score/ IDS-score < 12
number of ECT treatments needed to achieve response/remission
Neurocognitive performance (RAVLT)
mean scores on RAVLT (Rey Auditory Verbal Learning Test)
Neurocognitive performance (MoCA)
mean scores on MoCA (Montreal Cognitive Assessment)
Neurocognitive performance (COWAT)
mean scores on COWAT (Controlled Oral Word Association Test)
Neurocognitive performance (WMS-R)
mean scores on WMS-R (Wechsler Memory Scale) (Cijferreeksen)

Full Information

First Posted
June 1, 2023
Last Updated
June 19, 2023
Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Universiteit Antwerpen, AZ Sint-Jan AV, General Hospital Groeninge
search

1. Study Identification

Unique Protocol Identification Number
NCT05923801
Brief Title
Changing Tactics? Optimizing ECT in Difficult-to-treat Depression
Acronym
ChaT
Official Title
Changing Tactics? Optimizing ECT in Difficult-to-treat Depression: A Randomized Trial Comparing Continuation of Right Unilateral ECT and Switching to Bitemporal ECT in Case of Early Non-response During an Acute Course of ECT for Difficult-to-treat Depression
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2023 (Actual)
Primary Completion Date
June 1, 2026 (Anticipated)
Study Completion Date
June 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Universiteit Antwerpen, AZ Sint-Jan AV, General Hospital Groeninge

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this randomized controlled trial is to address which treatment strategy (continue right unilateral (RUL) ECT or switch to bitemporal (BT) ECT speeds up recovery and has the least impact on memory function, in case of early non-response during an acute course of ECT for difficult-to-treat depression. The main questions it aims to answer are: Assess the antidepressant efficacy and cognitive impact of the continuation of an ongoing treatment with RUL ECT compared to switching the treatment technique to BT ECT, in patients failing to show an early response to an acute course of ECT for major depression; Assess group and subject-specific trajectories of depressive symptom severity and neurocognitive performance during the acute ECT course and up to 3 months post-treatment. Participants treated with ECT for depression, showing no 'response' (≥50 percent decrease in depressive symptom severity compared to baseline) after 4 treatment sessions, will be randomized to either switch to BT ECT or continue with RUL ECT. Mood and neurocognitive assessments will be performed at baseline, after 4 ECT sessions (before randomization), after 8 ECT sessions, at the end of the acute course and 3 month after the acute course.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
Keywords
Electroconvulsive Therapy, Depression, Cognition

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants treated with ECT for depression, showing no 'response' (≥50 percent decrease in depressive symptom severity compared to baseline) after 4 treatment sessions will be randomized into 2 treatment groups: either continuation with RUL ECT or switch to BT ECT.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
196 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BT ECT
Arm Type
Active Comparator
Arm Description
Participants showing no response will be switched to BT ECT until remission is achieved.
Arm Title
RUL ECT
Arm Type
Active Comparator
Arm Description
Participants showing no response will continue with RUL ECT until remission is achieved.
Intervention Type
Device
Intervention Name(s)
switch to BT electrode position
Intervention Description
use of different electrode positions of ECT device
Intervention Type
Device
Intervention Name(s)
continue with RUL electrode position
Intervention Description
use of different electrode positions of ECT device
Primary Outcome Measure Information:
Title
Change form baseline Depressive Symptom Severity
Description
mean scores on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR)
Time Frame
after 4 ECT sessions (2 weeks)
Title
Change form baseline Depressive Symptom Severity
Description
mean scores on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR)
Time Frame
after 8 ECT sessions (4 weeks)
Title
Depressive Symptom Severity
Description
mean scores on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR)
Time Frame
at the end of acute ECT course (up to 7 weeks)
Title
Depressive Symptom Severity
Description
mean scores on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR)
Time Frame
3 months post-acute course
Title
Autobiographical Memory
Description
Mean scores on the Colombia University Autobiographical Memory Interview Short Form (CU-AMI-SF)
Time Frame
after 4 ECT sessions (2 weeks)
Title
Autobiographical Memory
Description
Mean scores on the Colombia University Autobiographical Memory Interview Short Form (CU-AMI-SF)
Time Frame
after 8 ECT sessions (4 weeks)
Title
Autobiographical Memory
Description
Mean scores on the Colombia University Autobiographical Memory Interview Short Form (CU-AMI-SF)
Time Frame
at the end of acute ECT course (up to 7 weeks)
Title
Autobiographical Memory
Description
Mean scores on the Colombia University Autobiographical Memory Interview Short Form (CU-AMI-SF)
Time Frame
3 months post-acute course
Secondary Outcome Measure Information:
Title
Response/remission status
Description
number of participants with an 50 percent decrease in IDS-score/ IDS-score < 12
Time Frame
at the end of acute ECT course (up to 7 weeks)
Title
number of ECT treatments needed to achieve response/remission
Time Frame
at the end of acute ECT course (up to 7 weeks)
Title
Neurocognitive performance (RAVLT)
Description
mean scores on RAVLT (Rey Auditory Verbal Learning Test)
Time Frame
after 4 ECT sessions (2 weeks), after 8 ECT sessions (4 weeks), at the end of acute ECT course (up to 7 weeks), 3 months post-acute course
Title
Neurocognitive performance (MoCA)
Description
mean scores on MoCA (Montreal Cognitive Assessment)
Time Frame
after 4 ECT sessions (2 weeks), after 8 ECT sessions (4 weeks), at the end of acute ECT course (up to 7 weeks), 3 months post-acute course
Title
Neurocognitive performance (COWAT)
Description
mean scores on COWAT (Controlled Oral Word Association Test)
Time Frame
after 4 ECT sessions (2 weeks), after 8 ECT sessions (4 weeks), at the end of acute ECT course (up to 7 weeks), 3 months post-acute course
Title
Neurocognitive performance (WMS-R)
Description
mean scores on WMS-R (Wechsler Memory Scale) (Cijferreeksen)
Time Frame
after 4 ECT sessions (2 weeks), after 8 ECT sessions (4 weeks), at the end of acute ECT course (up to 7 weeks), 3 months post-acute course
Other Pre-specified Outcome Measures:
Title
Clinical characteristics (CORE)
Description
mean scores on CORE
Time Frame
after 4 ECT sessions (2 weeks), after 8 ECT sessions (4 weeks), at the end of acute ECT course (up to 7 weeks), 3 months post-acute course
Title
Clinical characteristics (PDAS)
Description
mean scores on PDAS
Time Frame
after 4 ECT sessions (2 weeks), after 8 ECT sessions (4 weeks), at the end of acute ECT course (up to 7 weeks), 3 months post-acute course

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures Age 18 or older Diagnosis of major depressive disorder (DSM-5 296.21-30) or bipolar disorder, depressed (DSM-5 296.51-54; 296.84), confirmed by MINI (Mini International Neuropsychiatric Interview) Exclusion Criteria: Contra-indication for general anesthesia Non-Dutch speaking Diagnosis of schizoaffective disorder or schizophrenia, confirmed by MINI Diagnosis of substance use disorder in the past six months, confirmed by MINI Diagnosis of neurocognitive disorder or intellectual disability alongside a MoCA score <23 Previous ECT course in the past three months Participation in an interventional Trial with an investigational medicinal product or device Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pascal Sienaert, MD,PhD
Phone
+322 758 05 11
Email
pascal.sienaert@upckuleuven.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pascal Sienaert, MD, PhD
Organizational Affiliation
UPC KU Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
UPC Kortenberg
City
Kortenberg
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pascal Sienaert, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Details on methodology are noted in the protocol. Questionnaires will be used as stated in their manuals. Data of assessments (informed consent, answers to questionnaires,...) are documented on paper and entered in a data platform (Redcap). When access is provided, or data is exported (using a certain standard format such as .xls or .cvs) it can be reused by other researchers. All data is provided with a clear nomenclature, referring to the scores of standardized questionnaires,cognitive assessment tools, ECT parameters,... Further, published articles by the involved researchers will contain all details necessary to reveal context of data collection, collection methodology, analytical and procedural information, etc. The pseudonymized data can be made available upon request, after permission is granted by the principal investigator and the head researchers.
Citations:
PubMed Identifier
27780482
Citation
Kolshus E, Jelovac A, McLoughlin DM. Bitemporal v. high-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials. Psychol Med. 2017 Feb;47(3):518-530. doi: 10.1017/S0033291716002737. Epub 2016 Oct 26. Erratum In: Psychol Med. 2017 Sep 18;:1-2.
Results Reference
background
PubMed Identifier
26892939
Citation
Semkovska M, Landau S, Dunne R, Kolshus E, Kavanagh A, Jelovac A, Noone M, Carton M, Lambe S, McHugh C, McLoughlin DM. Bitemporal Versus High-Dose Unilateral Twice-Weekly Electroconvulsive Therapy for Depression (EFFECT-Dep): A Pragmatic, Randomized, Non-Inferiority Trial. Am J Psychiatry. 2016 Apr 1;173(4):408-17. doi: 10.1176/appi.ajp.2015.15030372. Epub 2016 Feb 19.
Results Reference
background
PubMed Identifier
20194546
Citation
Kellner CH, Knapp R, Husain MM, Rasmussen K, Sampson S, Cullum M, McClintock SM, Tobias KG, Martino C, Mueller M, Bailine SH, Fink M, Petrides G. Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial. Br J Psychiatry. 2010 Mar;196(3):226-34. doi: 10.1192/bjp.bp.109.066183.
Results Reference
background
PubMed Identifier
32585354
Citation
Sackeim HA, Prudic J, Devanand DP, Nobler MS, Haskett RF, Mulsant BH, Rosenquist PB, McCall WV. The benefits and costs of changing treatment technique in electroconvulsive therapy due to insufficient improvement of a major depressive episode. Brain Stimul. 2020 Sep-Oct;13(5):1284-1295. doi: 10.1016/j.brs.2020.06.016. Epub 2020 Jun 22.
Results Reference
background
PubMed Identifier
21681108
Citation
Lapidus KA, Kellner CH. When to switch from unilateral to bilateral electroconvulsive therapy. J ECT. 2011 Sep;27(3):244-6. doi: 10.1097/YCT.0b013e31820059e1. No abstract available.
Results Reference
background
PubMed Identifier
31104321
Citation
Birkenhager TK, Roos J, Kamperman AM. Improvement after two sessions of electroconvulsive therapy predicts final remission in in-patients with major depression. Acta Psychiatr Scand. 2019 Sep;140(3):189-195. doi: 10.1111/acps.13054. Epub 2019 Jun 7.
Results Reference
background
PubMed Identifier
8733206
Citation
Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996 May;26(3):477-86. doi: 10.1017/s0033291700035558.
Results Reference
background
PubMed Identifier
29436330
Citation
van Diermen L, van den Ameele S, Kamperman AM, Sabbe BCG, Vermeulen T, Schrijvers D, Birkenhager TK. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. Br J Psychiatry. 2018 Feb;212(2):71-80. doi: 10.1192/bjp.2017.28. Erratum In: Br J Psychiatry. 2018 May;212(5):322.
Results Reference
background
PubMed Identifier
17074942
Citation
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905-17. doi: 10.1176/ajp.2006.163.11.1905.
Results Reference
background
PubMed Identifier
35048827
Citation
Kirov G, Jauhar S, Sienaert P, Kellner CH, McLoughlin DM. Electroconvulsive therapy for depression: 80 years of progress. Br J Psychiatry. 2021 Nov;219(5):594-597. doi: 10.1192/bjp.2021.37.
Results Reference
background
PubMed Identifier
31774547
Citation
Kellner CH, Obbels J, Sienaert P. When to consider electroconvulsive therapy (ECT). Acta Psychiatr Scand. 2020 Apr;141(4):304-315. doi: 10.1111/acps.13134. Epub 2019 Dec 23.
Results Reference
background
PubMed Identifier
17146008
Citation
Kellner CH, Knapp RG, Petrides G, Rummans TA, Husain MM, Rasmussen K, Mueller M, Bernstein HJ, O'Connor K, Smith G, Biggs M, Bailine SH, Malur C, Yim E, McClintock S, Sampson S, Fink M. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry. 2006 Dec;63(12):1337-44. doi: 10.1001/archpsyc.63.12.1337.
Results Reference
background
PubMed Identifier
27418379
Citation
Kellner CH, Husain MM, Knapp RG, McCall WV, Petrides G, Rudorfer MV, Young RC, Sampson S, McClintock SM, Mueller M, Prudic J, Greenberg RM, Weiner RD, Bailine SH, Rosenquist PB, Raza A, Kaliora S, Latoussakis V, Tobias KG, Briggs MC, Liebman LS, Geduldig ET, Teklehaimanot AA, Lisanby SH; CORE/PRIDE Work Group. Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase 1 of the PRIDE Study. Am J Psychiatry. 2016 Nov 1;173(11):1101-1109. doi: 10.1176/appi.ajp.2016.15081101. Epub 2016 Jul 15.
Results Reference
background
PubMed Identifier
20673880
Citation
Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010 Sep 15;68(6):568-77. doi: 10.1016/j.biopsych.2010.06.009. Epub 2010 Jul 31.
Results Reference
background
PubMed Identifier
3314538
Citation
Sackeim HA, Decina P, Kanzler M, Kerr B, Malitz S. Effects of electrode placement on the efficacy of titrated, low-dose ECT. Am J Psychiatry. 1987 Nov;144(11):1449-55. doi: 10.1176/ajp.144.11.1449.
Results Reference
background
PubMed Identifier
15119910
Citation
Husain MM, Rush AJ, Fink M, Knapp R, Petrides G, Rummans T, Biggs MM, O'Connor K, Rasmussen K, Litle M, Zhao W, Bernstein HJ, Smith G, Mueller M, McClintock SM, Bailine SH, Kellner CH. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry. 2004 Apr;65(4):485-91. doi: 10.4088/jcp.v65n0406.
Results Reference
background
PubMed Identifier
29656263
Citation
Martinez-Amoros E, Goldberg X, Galvez V, de Arriba-Arnau A, Soria V, Menchon JM, Palao DJ, Urretavizcaya M, Cardoner N. Early improvement as a predictor of final remission in major depressive disorder: New insights in electroconvulsive therapy. J Affect Disord. 2018 Aug 1;235:169-175. doi: 10.1016/j.jad.2018.03.014. Epub 2018 Apr 6.
Results Reference
background

Learn more about this trial

Changing Tactics? Optimizing ECT in Difficult-to-treat Depression

We'll reach out to this number within 24 hrs